Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Coordinated Care in Breast Oncology: Encouraging Participation in Clinical Trials

August 4th 2025

Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Coordinated Care in Breast Oncology: Systemic Therapy Trials and Personalized Approaches

August 1st 2025

Experts explore how advances in systemic therapy are helping personalize and de-escalate breast cancer treatment.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Coordinated Care in Breast Oncology: Tumor Board & Treatment Alignment

July 31st 2025

Experts discuss how coordinated tumor board reviews enhance continuity of care, treatment personalization, and patient confidence after breast cancer surgery.

Coordinated Care in Breast Oncology: Importance of Plastic Surgery & Genetic Counseling

July 30th 2025

Experts discuss how involving plastic surgeons and genetic counselors early in breast cancer care helps guide personalized surgical decisions.

Coordinated Care in Breast Oncology: Role of Radiation Oncology

July 29th 2025

Experts discuss the importance of early multidisciplinary collaboration in breast cancer care, particularly involving radiation oncology at diagnosis.

Coordinated Care in Breast Oncology: Benefits of the Multidisciplinary Clinic

July 28th 2025

Experts discuss how a multidisciplinary clinic streamlines care and improves treatment planning for patients with newly diagnosed breast cancer.

Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC

July 27th 2025

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC

July 26th 2025

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML

July 9th 2025

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC

July 5th 2025

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.